{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:31:11Z","timestamp":1790310671984,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T00:00:00Z","timestamp":1592870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T00:00:00Z","timestamp":1592870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HI19C0430"],"award-info":[{"award-number":["HI19C0430"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s10549-020-05750-y","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T21:02:23Z","timestamp":1592946143000},"page":"107-116","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer"],"prefix":"10.1007","volume":"183","author":[{"given":"Ahrong","family":"Ham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gun Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Hung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Ye","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung Seok","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seho","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Up","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byeong Woo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Il","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2303-2764","authenticated-orcid":false,"given":"Joohyuk","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,23]]},"reference":[{"issue":"7","key":"5750_CR1","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","volume":"13","author":"B O'Leary","year":"2016","unstructured":"O'Leary B, Finn RS, Turner NC (2016) Treating cancer with selective CDK4\/6 inhibitors. Nat Rev Clin Oncol 13(7):417\u2013430. https:\/\/doi.org\/10.1038\/nrclinonc.2016.26","journal-title":"Nat Rev Clin Oncol"},{"issue":"20","key":"5750_CR2","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS et al (2016) Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med 375(20):1925\u20131936. https:\/\/doi.org\/10.1056\/NEJMoa1607303","journal-title":"N Engl J Med"},{"issue":"10","key":"5750_CR3","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1634\/theoncologist.2016-0097","volume":"21","author":"S Verma","year":"2016","unstructured":"Verma S, Bartlett CH, Schnell P et al (2016) Palbociclib in combination with fulvestrant in women with hormone receptor-positive\/her2-negative advanced metastatic breast cancer: detailed safety analysis from a multicenter, randomized, placebo-controlled, phase III study (PALOMA-3). Oncologist 21(10):1165\u20131175. https:\/\/doi.org\/10.1634\/theoncologist.2016-0097","journal-title":"Oncologist"},{"issue":"4","key":"5750_CR4","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1903765","volume":"381","author":"SA Im","year":"2019","unstructured":"Im SA, Lu YS, Bardia A et al (2019) Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med 381(4):307\u2013316. https:\/\/doi.org\/10.1056\/NEJMoa1903765","journal-title":"N Engl J Med"},{"issue":"32","key":"5750_CR5","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz MP, Toi M, Campone M et al (2017) MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 35(32):3638\u20133646. https:\/\/doi.org\/10.1200\/JCO.2017.75.6155","journal-title":"J Clin Oncol"},{"issue":"10","key":"5750_CR6","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/S1470-2045(19)30420-6","volume":"20","author":"M Giuliano","year":"2019","unstructured":"Giuliano M, Schettini F, Rognoni C et al (2019) Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Lancet Oncol 20(10):1360\u20131369. https:\/\/doi.org\/10.1016\/S1470-2045(19)30420-6","journal-title":"Lancet Oncol"},{"key":"5750_CR7","doi-asserted-by":"publisher","first-page":"175883591879332","DOI":"10.1177\/1758835918793326","volume":"10","author":"M Thill","year":"2018","unstructured":"Thill M, Schmidt M (2018) Management of adverse events during cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitor-based treatment in breast cancer. Ther Adv Med Oncol 10:1758835918793326. https:\/\/doi.org\/10.1177\/1758835918793326","journal-title":"Ther Adv Med Oncol"},{"key":"5750_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JGO.18.00173","volume":"5","author":"SA Im","year":"2019","unstructured":"Im SA, Mukai H, Park IH et al (2019) Palbociclib plus letrozole as first-line therapy in postmenopausal asian women with metastatic breast cancer: results from the phase III, randomized PALOMA-2 study. J Glob Oncol 5:1\u201319. https:\/\/doi.org\/10.1200\/JGO.18.00173","journal-title":"J Glob Oncol"},{"issue":"8","key":"5750_CR9","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1158\/1078-0432.Ccr-15-1421","volume":"22","author":"W Hu","year":"2016","unstructured":"Hu W, Sung T, Jessen BA et al (2016) Mechanistic investigation of bone marrow suppression associated with palbociclib and its differentiation from cytotoxic chemotherapies. Clin Cancer Res 22(8):2000\u20132008. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-1421","journal-title":"Clin Cancer Res"},{"issue":"9","key":"5750_CR10","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1093\/annonc\/mdz198","volume":"30","author":"EL Mayer","year":"2019","unstructured":"Mayer EL, DeMichele A, Rugo HS et al (2019) A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma. Ann Oncol 30(9):1514\u20131520. https:\/\/doi.org\/10.1093\/annonc\/mdz198","journal-title":"Ann Oncol"},{"issue":"1","key":"5750_CR11","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1016\/j.clbc.2018.09.002","volume":"19","author":"GA Watson","year":"2019","unstructured":"Watson GA, Deac O, Aslam R et al (2019) Real-world experience of palbociclib-induced adverse events and compliance with complete blood count monitoring in women with hormone receptor-positive\/her2-negative metastatic breast cancer. Clin Breast Cancer 19(1):e186\u2013e194. https:\/\/doi.org\/10.1016\/j.clbc.2018.09.002","journal-title":"Clin Breast Cancer"},{"issue":"9","key":"5750_CR12","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1634\/theoncologist.2017-0142","volume":"22","author":"LM Spring","year":"2017","unstructured":"Spring LM, Zangardi ML, Moy B et al (2017) Clinical management of potential toxicities and drug interactions related to cyclin-dependent kinase 4\/6 inhibitors in breast cancer: practical considerations and recommendations. Oncologist 22(9):1039\u20131048. https:\/\/doi.org\/10.1634\/theoncologist.2017-0142","journal-title":"Oncologist"},{"issue":"8","key":"5750_CR13","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","volume":"29","author":"F Cardoso","year":"2018","unstructured":"Cardoso F, Senkus E, Costa A et al (2018) 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)dagger. Ann Oncol 29(8):1634\u20131657. https:\/\/doi.org\/10.1093\/annonc\/mdy192","journal-title":"Ann Oncol"},{"key":"5750_CR14","doi-asserted-by":"crossref","unstructured":"Mayer E, DeMichele A, Dubsky P et al (2016) Abstract OT1\u201303\u201321: PALLAS: PAlbociclib Collaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for HR+\/HER2-early breast cancer. AACR","DOI":"10.1158\/1538-7445.SABCS15-OT1-03-21"},{"issue":"9","key":"5750_CR15","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1093\/annonc\/mdz191","volume":"30","author":"A Mansinho","year":"2019","unstructured":"Mansinho A, Boni V, Miguel M et al (2019) New designs in early clinical drug development. Ann Oncol 30(9):1460\u20131465. https:\/\/doi.org\/10.1093\/annonc\/mdz191","journal-title":"Ann Oncol"},{"issue":"30","key":"5750_CR16","doi-asserted-by":"publisher","first-page":"4594","DOI":"10.1200\/JCO.2010.28.8415","volume":"28","author":"A Di Leo","year":"2010","unstructured":"Di Leo A, Jerusalem G, Petruzelka L et al (2010) Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 28(30):4594\u20134600. https:\/\/doi.org\/10.1200\/JCO.2010.28.8415","journal-title":"J Clin Oncol"},{"issue":"6","key":"5750_CR17","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.ejca.2014.01.025","volume":"50","author":"YG Najjar","year":"2014","unstructured":"Najjar YG, Mittal K, Elson P et al (2014) A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. Eur J Cancer 50(6):1084\u20131089. https:\/\/doi.org\/10.1016\/j.ejca.2014.01.025","journal-title":"Eur J Cancer"},{"issue":"18","key":"5750_CR18","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1200\/JCO.2005.05.064","volume":"23","author":"A Arnold","year":"2005","unstructured":"Arnold A, Papanikolaou A (2005) Cyclin D1 in breast cancer pathogenesis. J Clin Oncol 23(18):4215\u20134224. https:\/\/doi.org\/10.1200\/JCO.2005.05.064","journal-title":"J Clin Oncol"},{"issue":"1","key":"5750_CR19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ccr.2005.12.012","volume":"9","author":"Q Yu","year":"2006","unstructured":"Yu Q, Sicinska E, Geng Y et al (2006) Requirement for CDK4 kinase function in breast cancer. Cancer Cell 9(1):23\u201332. https:\/\/doi.org\/10.1016\/j.ccr.2005.12.012","journal-title":"Cancer Cell"},{"issue":"5","key":"5750_CR20","doi-asserted-by":"publisher","first-page":"R77","DOI":"10.1186\/bcr2419","volume":"11","author":"RS Finn","year":"2009","unstructured":"Finn RS, Dering J, Conklin D et al (2009) PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 11(5):R77. https:\/\/doi.org\/10.1186\/bcr2419","journal-title":"Breast Cancer Res"},{"issue":"1","key":"5750_CR21","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1182\/blood-2014-06-584417","volume":"125","author":"R Scheicher","year":"2015","unstructured":"Scheicher R, Hoelbl-Kovacic A, Bellutti F et al (2015) CDK6 as a key regulator of hematopoietic and leukemic stem cell activation. Blood 125(1):90\u2013101. https:\/\/doi.org\/10.1182\/blood-2014-06-584417","journal-title":"Blood"},{"issue":"23","key":"5750_CR22","doi-asserted-by":"publisher","first-page":"6120","DOI":"10.1182\/blood-2010-08-300517","volume":"117","author":"MG Hu","year":"2011","unstructured":"Hu MG, Deshpande A, Schlichting N et al (2011) CDK6 kinase activity is required for thymocyte development. Blood 117(23):6120\u20136131. https:\/\/doi.org\/10.1182\/blood-2010-08-300517","journal-title":"Blood"},{"issue":"18","key":"5750_CR23","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA et al (2016) Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med 375(18):1738\u20131748. https:\/\/doi.org\/10.1056\/NEJMoa1609709","journal-title":"N Engl J Med"}],"updated-by":[{"DOI":"10.1007\/s10549-020-05796-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T00:00:00Z","timestamp":1594684800000}}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05750-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-020-05750-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05750-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:16:16Z","timestamp":1624407376000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-020-05750-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,23]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["5750"],"URL":"https:\/\/doi.org\/10.1007\/s10549-020-05750-y","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10549-020-05796-y","asserted-by":"object"}]},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,23]]},"assertion":[{"value":"23 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the original publication of the article, under the Results section, subheading \ufffd\ufffd\ufffdPatient survival\ufffd\ufffd\ufffd, the second sentence that reads as \ufffd\ufffd\ufffdThe 6-month PFS was 92.4%, 81.8%, and 93.3% and the one-year PFS was 72.0%, 88.9%, and 78.9% in Groups 1\ufffd\ufffd\ufffd3, respectively.\ufffd\ufffd\ufffd should read as \"The 6-month PFS was 82.8%, 75.0%, and 68.0% and the one-year PFS was 77.0%, 62.0%, and 63.8% in Groups 1\ufffd\ufffd\ufffd3, respectively.\".","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was approved by the Institutional Review Board of Severance Hospital. All procedures performed in this study were in accordance with the ethical standards of the Institutional Review Board and with the 1964 Helsinki declaration.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was waived because this study is a retrospective medical chart review that has minimal level of risk.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}